Jefferies London: Sofinnova Partners announced a new $750M fund XI today that will invest in early stage companies in biotech
Chairman and managing partner Antoine Papiernik tells us about the fund and how he expects to deploy it. Plus, the current state of European biotech.
--------
10:26
--------
10:26
Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech
He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific.
--------
4:41
--------
4:41
Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.
--------
4:12
--------
4:12
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
CEO Michael Henderson walks us through what will be a busy year for the company.
--------
12:26
--------
12:26
Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
España